NR546 WEEK 8 FINAL EXAM COMPLETE
QUESTION BANK QUESTIONS, ANSWERS
& RATIONALES PMHNP ADVANCED
PSYCHOPHARMACOLOGY REVIEW GUIDE
(LATEST 2026 EDITION)
This comprehensive, high-density study resource features proctored
multiple-choice questions, accurate answers, and detailed, bolded
rationales tailored specifically for the NR546 Advanced
Psychopharmacology curriculum. It systematically covers complex
clinical blueprints including neurotransmitter pathways, mood
stabilizers, atypical antipsychotics, FDA-approved pediatric
guidelines, and critical drug-drug interactions. Designed directly for
PMHNP students, this premium guide guarantees mastery over the
challenging final exam material and maximizes your academic
performance.
Question 1
A 28-year-old female patient diagnosed with Major Depressive Disorder
(MDD) has failed to respond to adequate 8-week trials of both sertraline
and escitalopram. Which of the following is the most appropriate next
clinical step?
A) Initiate a third Selective Serotonin Reuptake Inhibitor (SSRI).
B) Switch to a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) like
duloxetine.
C) Immediately add phenelzine to the current SSRI regimen.
D) Discontinue all medications and start maintenance ECT.
,Answer: B
Rationale: After failing two adequate trials of SSRIs, clinical
guidelines recommend switching to a different class of
antidepressants, such as an SNRI (e.g., duloxetine or venlafaxine).
Switching to a third SSRI is unlikely to yield a response, combining an
SSRI with an MAOI is contraindicated due to fatal serotonin
syndrome, and ECT is typically reserved for treatment-resistant
depression after broader pharmacological failures.
Question 2
A patient taking clozapine for treatment-resistant schizophrenia presents for
routine lab monitoring. The Absolute Neutrophil Count (ANC) is reported as
950/μL. Which action must the PMHNP take?
A) Continue the current dose and repeat the lab work in one month.
B) Reduce the dose of clozapine by half and monitor ANC weekly.
C) Immediately interrupt clozapine therapy, monitor ANC daily, and consult
hematology.
D) Add lithium carbonate to artificially boost the white blood cell count.
Answer: C
Rationale: An ANC below 1,000/μL constitutes severe neutropenia.
According to the Clozapine REMS registry guidelines, clozapine
therapy must be immediately interrupted, the patient monitored
closely with daily ANCs until recovery, and hematology consulted.
Continuing or merely reducing the dose poses a critical risk of life-
threatening agranulocytosis.
Question 3
Which dopamine pathway is primarily associated with the development of
extrapyramidal symptoms (EPS) and tardive dyskinesia following prolonged
use of first-generation antipsychotics?
A) Mesolimbic pathway
B) Mesocortical pathway
,C) Nigrostriatal pathway
D) Tuberoinfundibular pathway
Answer: C
Rationale: The nigrostriatal dopamine pathway controls motor
movement. Chronic D₂ receptor antagonism in this pathway leads to
extrapyramidal side effects, dystonia, parkinsonism, and tardive
dyskinesia. In contrast, the mesolimbic pathway mediates psychosis,
the mesocortical mediates negative symptoms, and the
tuberoinfundibular regulates prolactin release.
Question 4
A 34-year-old male with Bipolar I Disorder presents with acute mania. His
laboratory baseline shows compromised renal function with an estimated
Glomerular Filtration Rate (eGFR) of 45 mL/min/1.73m². Which mood
stabilizer is most appropriate to initiate?
A) Lithium carbonate
B) Valproic acid
C) Topiramate
D) Carbamazepine
Answer: B
Rationale: Valproic acid (Depakote) is primarily metabolized by the
liver, making it a safer and highly effective alternative for patients with
compromised renal clearance. Lithium is entirely cleared by the
kidneys and is contraindicated or requires extreme caution in renal
impairment due to an elevated risk of severe toxicity.
Question 5
A patient being titrated on lamotrigine for Bipolar Depression presents to
the clinic with a mild, non-painful maculopapular rash on her trunk, with no
mucosal involvement or systemic symptoms. What is the most appropriate
action?
A) Reassure the patient and continue the current titration schedule.
, B) Decrease the dose of lamotrigine by half and monitor closely.
C) Discontinue lamotrigine immediately and instruct the patient to seek
emergency care.
D) Prescribe an oral corticosteroid and continue lamotrigine.
Answer: C
Rationale: Because any rash associated with lamotrigine can rapidly
progress to life-threatening Stevens-Johnson Syndrome (SJS) or
Toxic Epidermal Necrolysis (TEN), clinical guidelines mandate
immediate discontinuation of the drug at the first sign of a rash. Re-
challenging or continuing titration poses unacceptable legal and
medical risks.
Question 6
A 72-year-old patient diagnosed with Alzheimer's disease is prescribed
donepezil. What is the primary mechanism of action of this medication?
A) Reversible inhibition of acetylcholinesterase to increase synaptic
acetylcholine.
B) NMDA receptor antagonism to reduce glutamate excitotoxicity.
C) Selective serotonin and norepinephrine reuptake inhibition.
D) Dopamine receptor agonism in the prefrontal cortex.
Answer: A
Rationale: Donepezil is a reversible acetylcholinesterase inhibitor that
works by blocking the enzyme responsible for breaking down
acetylcholine, thereby enhancing cholinergic neurotransmission to
temporarily improve or stabilize cognitive function. Memantine, not
donepezil, acts as an NMDA receptor antagonist.
Question 7
A PMHNP is evaluating a patient taking phenelzine who consumed aged
cheese and red wine at a party. The patient presents with a severe occipital
headache, palpitations, and a blood pressure of 210/120 mmHg. Which
acute condition is occurring?
QUESTION BANK QUESTIONS, ANSWERS
& RATIONALES PMHNP ADVANCED
PSYCHOPHARMACOLOGY REVIEW GUIDE
(LATEST 2026 EDITION)
This comprehensive, high-density study resource features proctored
multiple-choice questions, accurate answers, and detailed, bolded
rationales tailored specifically for the NR546 Advanced
Psychopharmacology curriculum. It systematically covers complex
clinical blueprints including neurotransmitter pathways, mood
stabilizers, atypical antipsychotics, FDA-approved pediatric
guidelines, and critical drug-drug interactions. Designed directly for
PMHNP students, this premium guide guarantees mastery over the
challenging final exam material and maximizes your academic
performance.
Question 1
A 28-year-old female patient diagnosed with Major Depressive Disorder
(MDD) has failed to respond to adequate 8-week trials of both sertraline
and escitalopram. Which of the following is the most appropriate next
clinical step?
A) Initiate a third Selective Serotonin Reuptake Inhibitor (SSRI).
B) Switch to a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) like
duloxetine.
C) Immediately add phenelzine to the current SSRI regimen.
D) Discontinue all medications and start maintenance ECT.
,Answer: B
Rationale: After failing two adequate trials of SSRIs, clinical
guidelines recommend switching to a different class of
antidepressants, such as an SNRI (e.g., duloxetine or venlafaxine).
Switching to a third SSRI is unlikely to yield a response, combining an
SSRI with an MAOI is contraindicated due to fatal serotonin
syndrome, and ECT is typically reserved for treatment-resistant
depression after broader pharmacological failures.
Question 2
A patient taking clozapine for treatment-resistant schizophrenia presents for
routine lab monitoring. The Absolute Neutrophil Count (ANC) is reported as
950/μL. Which action must the PMHNP take?
A) Continue the current dose and repeat the lab work in one month.
B) Reduce the dose of clozapine by half and monitor ANC weekly.
C) Immediately interrupt clozapine therapy, monitor ANC daily, and consult
hematology.
D) Add lithium carbonate to artificially boost the white blood cell count.
Answer: C
Rationale: An ANC below 1,000/μL constitutes severe neutropenia.
According to the Clozapine REMS registry guidelines, clozapine
therapy must be immediately interrupted, the patient monitored
closely with daily ANCs until recovery, and hematology consulted.
Continuing or merely reducing the dose poses a critical risk of life-
threatening agranulocytosis.
Question 3
Which dopamine pathway is primarily associated with the development of
extrapyramidal symptoms (EPS) and tardive dyskinesia following prolonged
use of first-generation antipsychotics?
A) Mesolimbic pathway
B) Mesocortical pathway
,C) Nigrostriatal pathway
D) Tuberoinfundibular pathway
Answer: C
Rationale: The nigrostriatal dopamine pathway controls motor
movement. Chronic D₂ receptor antagonism in this pathway leads to
extrapyramidal side effects, dystonia, parkinsonism, and tardive
dyskinesia. In contrast, the mesolimbic pathway mediates psychosis,
the mesocortical mediates negative symptoms, and the
tuberoinfundibular regulates prolactin release.
Question 4
A 34-year-old male with Bipolar I Disorder presents with acute mania. His
laboratory baseline shows compromised renal function with an estimated
Glomerular Filtration Rate (eGFR) of 45 mL/min/1.73m². Which mood
stabilizer is most appropriate to initiate?
A) Lithium carbonate
B) Valproic acid
C) Topiramate
D) Carbamazepine
Answer: B
Rationale: Valproic acid (Depakote) is primarily metabolized by the
liver, making it a safer and highly effective alternative for patients with
compromised renal clearance. Lithium is entirely cleared by the
kidneys and is contraindicated or requires extreme caution in renal
impairment due to an elevated risk of severe toxicity.
Question 5
A patient being titrated on lamotrigine for Bipolar Depression presents to
the clinic with a mild, non-painful maculopapular rash on her trunk, with no
mucosal involvement or systemic symptoms. What is the most appropriate
action?
A) Reassure the patient and continue the current titration schedule.
, B) Decrease the dose of lamotrigine by half and monitor closely.
C) Discontinue lamotrigine immediately and instruct the patient to seek
emergency care.
D) Prescribe an oral corticosteroid and continue lamotrigine.
Answer: C
Rationale: Because any rash associated with lamotrigine can rapidly
progress to life-threatening Stevens-Johnson Syndrome (SJS) or
Toxic Epidermal Necrolysis (TEN), clinical guidelines mandate
immediate discontinuation of the drug at the first sign of a rash. Re-
challenging or continuing titration poses unacceptable legal and
medical risks.
Question 6
A 72-year-old patient diagnosed with Alzheimer's disease is prescribed
donepezil. What is the primary mechanism of action of this medication?
A) Reversible inhibition of acetylcholinesterase to increase synaptic
acetylcholine.
B) NMDA receptor antagonism to reduce glutamate excitotoxicity.
C) Selective serotonin and norepinephrine reuptake inhibition.
D) Dopamine receptor agonism in the prefrontal cortex.
Answer: A
Rationale: Donepezil is a reversible acetylcholinesterase inhibitor that
works by blocking the enzyme responsible for breaking down
acetylcholine, thereby enhancing cholinergic neurotransmission to
temporarily improve or stabilize cognitive function. Memantine, not
donepezil, acts as an NMDA receptor antagonist.
Question 7
A PMHNP is evaluating a patient taking phenelzine who consumed aged
cheese and red wine at a party. The patient presents with a severe occipital
headache, palpitations, and a blood pressure of 210/120 mmHg. Which
acute condition is occurring?
